ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2120 • ACR Convergence 2022

    Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis

    Bruce Strober1, Laura Coates2, Jenny Yu3, Katelyn Rowland4, Evan Leibowitz4, Megan Miller5, Alexa Kollmeier6, Shu Li5, Yanli Wang5, Daphne Chan4, Soumya Chakravarty7, Ya-Wen Yang8, May Shawi8, Mark Lebwohl9 and Proton Rahman10, 1Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, USA, San Diego, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA, 6Janssen-Cilag, Research & Development, LLC, San Diego, CA, 7Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 8Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 9Icahn School of Medicine at Mount Sinai, New York, NY, 10Memorial University, St. John's, NL, Canada

    Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, inhibiting its function. GUS has been shown…
  • Abstract Number: 2246 • ACR Convergence 2022

    Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes

    Kelly O'Neill1, Pamela Sinicrope2, Cynthia Crowson3, Kathryne Marks4, Rachel Giblon5, Elena Myasoedova2 and John Davis2, 1Rheumatoid Patient Foundation, Winter Springs, FL, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4Brigham and Women's Hospital, Boston, MA, 5Mayo Clinic, Rochester, MN, Rochester, MN

    Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
  • Abstract Number: 2245 • ACR Convergence 2022

    Feasibility and Efficacy of a Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials

    Saira Sheikh1, Caroline Donovan2, Carla Menezes2, Albert T. Roy2, Andrew Simkus3, Diane Gross4, Anca Askanase5, Rosalind Ramsey-Goldman6, Vikas Majithia7, Nicole Wanty3, Annie McNeill3, Kristen Holtz3 and S. Sam Lim8, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Lupus Therapeutics, LLC, New York, NY, 3KDH Research & Communication, Atlanta, GA, 4Lupus Research Alliance, New York, NY, 5Columbia University Medical Center, New York, NY, 6Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 7University of Mississippi Medical Center, Ridgeland, MS, 8Emory University, Atlanta, GA

    Background/Purpose: To assess outcomes related to Lupus Therapeutics' Patient Advocates for Lupus Studies (LT-PALS) a peer-to-peer clinical trial (CT) education program designed to improve CT…
  • Abstract Number: 2248 • ACR Convergence 2022

    Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort

    Gregory McDermott1, Keigo Hayashi2, Kazuki Yoshida1, Matthew Moll1, Michael Cho1, Tracy Doyle1, Paul Dellaripa1, Rachel Putman1, Raul San Jose Estepar1, George Washko1, Elizabeth Regan3, Hiroto Hatabu1, Gary M Hunninghake1, Edwin Silverman1 and Jeffrey Sparks4, 1Brigham and Women's Hospital, Boston, MA, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3National Jewish Health, Denver, CO, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
  • Abstract Number: 2237 • ACR Convergence 2022

    Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods

    Rohit Aggarwal1, Ingrid Lundberg2, Yeong-Wook Song3, Aziz Shaibani4, Victoria Werth5 and Michael Maldonado6, 1Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 3Seoul National University, Seoul, Republic of Korea, 4Nerve and Muscle Center of Texas, Houston, TX, 5Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 6Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
  • Abstract Number: 2117 • ACR Convergence 2022

    Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies

    Philip J Mease1, Laura Coates2, Robert Landewé3, Iain B McInnes4, Christopher Ritchlin5, Tatsuya Atsumi6, Frank Behrens7, Dafna Gladman8, Laure Gossec9, Peter Nash10, Barbara Ink11, Deepak Assudani11, Rajan Bajracharya11, Jason Coarse12, Adam R Prickett13 and Alice Gottlieb14, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Amsterdam University Medical Center, Meerssen, Netherlands, 4Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 6Hokkaido University, Sapporo, Japan, 7Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 8Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 9Sorbonne Université, Paris, France, 10School of Medicine, Griffith University, Sunshine Coast, Australia, 11UCB Pharma, Slough, United Kingdom, 12UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 13UCB Pharma, Brussels, Belgium, 14Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
  • Abstract Number: 1853 • ACR Convergence 2022

    A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease

    Mark Yun, Brianne Navetta-Modrov, Hafsa Nomani, Jie Yang and QingPing Yao, Stony Brook University, Stony Brook, NY

    Background/Purpose: NLRP3-associated autoinflammatoy disease (NLRP3-AID) and NLRP12-AID are rare autosomal dominant diseases. FACS1(familial cold autoinflammatory syndrome type 1), a subset of NLRP3-AID, is thought to…
  • Abstract Number: 2031 • ACR Convergence 2022

    Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

    Dong Xu1, Shangzhu Zhang1, Cibo Huang2, Chenghui Huang3, Li Qin4, Xiaomei Li5, Meiqing Chen6, Xiumei Liu7, Yi Liu8, Zhijun Li9, Jiankang Hu10, Chunde Bao11, wei Wei12, Jing Tian13, Xinwang Duan14, Jianmin Fang15 and Xiaofeng Zeng16, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Beijing Hospital, Beijing, China, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Huzhou Third Municipal Hospital, Huzhou, China, 5Anhui Provincial Hospital, Hefei, China, 6The First Affiliated Hospital of Xiamen University, Xiamen, China, 7The First Hospital of Shanxi Medical University, Taiyuan, China, 8West China Hospital of Sichuan University, Chengdu, China, 9The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 10Jiangxi Pingxiang People’s Hospital, Shanghai, China, 11Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 12Tianjin Medical University General Hospital, Tianjin, China, 13Second Xiangya Hospital of Central South University, Changsha, China, 14The Second Affiliated Hospital of Nanchang University, Nanchang, China, 15Shanghai Tongji Hospital, Shanghai, China, 16Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
  • Abstract Number: 2033 • ACR Convergence 2022

    Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology

    Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI

    Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
  • Abstract Number: 1849 • ACR Convergence 2022

    Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center

    Akash Gupta1, Paola Rivera Morales2 and Ninani Kombo2, 1Departmnt of Medicine, Yale University School of Medicine, New Haven, CT, 2Department of Ophthalmology & Visual Sciences, Yale School of Medicine, New Haven, CT

    Background/Purpose: Primary retinal vasculitis (PRV) refers to inflammation in the retinal vasculature without any infectious etiology, systemic disease association, or concomitant ocular disease. PRV is…
  • Abstract Number: 2032 • ACR Convergence 2022

    Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

    Kunal Chandwar1, Juhi Dixit1, Kriti Kishor1, DOGGA PRASANNA KUMAR2, DIGVIJAY EKBOTE3, PUNEET KUMAR1 and Urmila Dhakad1, 1King George's Medical University, Lucknow, India, 2KGMU, LUCKNOW, Uttar Pradesh, India, 3KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India

    Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
  • Abstract Number: 2034 • ACR Convergence 2022

    What Is the Best Initial Screening for Suspected Sjögren’s Disease?

    Katja Perdan Pirkmajer, Jelka Kramarič, matija Tomšič and Alojzija Hocevar, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: During the COVID-19 pandemic the routine diagnostic procedure in Sjögren's disease (SS) was highly hampered. The aim of our study was to determine in…
  • Abstract Number: 2036 • ACR Convergence 2022

    Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon

    Andres Martinez1, Julieta Morbiducci1, Constanza Arguissain1, Maria Tamborenea1, Marisel Bejarano2, Lucia Castorino1 and Anastasia Secco1, 1Rivadavia Hospital, Buenos Aires, Argentina, 2Rivadavia´s Hospital, Buenos Aires, Argentina

    Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
  • Abstract Number: 2039 • ACR Convergence 2022

    The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome

    Sarah Pringle1, Floris Bikker2, Wouter Vogel3, Ingrid Hofland3, Bert van der Vegt4, Hendrika Bootsma1, Frans Kroese1, Arjan Vissink5 and Matthijs Valstar3, 1University Medical Center Groningen, Groningen, Netherlands, 2ACTA, Amsterdam, Netherlands, 3NKI, Amsterdam, Netherlands, 4University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 5UMCG, Leek, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) often results in dysfunction of the salivary glands (hyposalivation and xerostomia) and substantial decrease in patient quality of life. High…
  • Abstract Number: 2040 • ACR Convergence 2022

    Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, R. Hal Scofield2, Kiely Grundahl1, Lida Radfar2, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
  • « Previous Page
  • 1
  • …
  • 418
  • 419
  • 420
  • 421
  • 422
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology